Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2021-09-06 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Next Day Disclosure Return' for an equity issuer, specifically detailing changes in issued share capital and share buybacks for World Houseware (Holdings) Limited. It includes detailed information about the exercise of share options, changes in issued shares, issue prices, and confirmations related to compliance with listing rules. The content focuses on share capital changes and disclosures pursuant to stock exchange rules, which aligns with announcements regarding share issues or capital changes. The document is about reporting changes in issued share capital and share buybacks, not a full financial report or earnings release. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length (7828 characters) and detailed data confirm it is not a mere announcement of a report but a substantive disclosure.
2021-09-06 English
VOLUNTARY ANNOUNCEMENT - GANNEX ANNOUNCES CLINICAL TRIAL APPLICATION OF ASC42, AN FXR AGONIST, FOR TREATMENT OF PRIMARY BILIARY CHOLANGITIS ACCEPTED BY CHINA NMPA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the acceptance of a clinical trial application for a drug (ASC42) by the China National Medical Products Administration (NMPA). It contains no financial data, no regulatory filings about financial performance, no voting results, no management changes, no earnings information, and no detailed financial or governance reports. The document is relatively short (3209 characters) and serves as a public announcement of a clinical trial application acceptance, which is a regulatory update related to the company's drug development pipeline. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or others that require financial data or detailed report content. It is not a report publication announcement since it is not announcing the release of a report but rather a clinical trial application acceptance. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2021-09-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2021
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on authorized and issued shares, share options, and other related capital changes for Ascletis Pharma Inc. It is addressed to the Hong Kong Exchanges and Clearing Limited and references the Exchange Listing Rules. The content includes detailed tables on share capital, share options, and confirmations related to securities movements. There is no indication that this is an annual or quarterly financial report, audit report, earnings release, or any other type of report. Instead, it is a regulatory filing related to share capital and securities movements, which fits the category of Share Issue/Capital Change announcements. The document length and detail confirm it is the report itself, not just an announcement of a report publication.
2021-09-03 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 August 2021
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return regarding movements in securities, specifically focusing on share capital, issued shares, share options, and confirmations related to securities issued by World Houseware (Holdings) Limited. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content is regulatory in nature, providing updates on share capital and share movements rather than financial performance or management commentary. It does not contain financial statements or earnings data, nor is it a report or presentation. It is a regulatory filing reporting share capital and securities movements for a specific month (August 2021). Therefore, the document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-09-01 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2021' and contains detailed unaudited condensed consolidated interim financial results for the six months ended June 30, 2021, including revenue, profit/loss, and detailed business and pipeline updates. It includes substantive financial data and management discussion and analysis for the half-year period. The presence of actual financial figures and detailed analysis confirms this is a comprehensive interim financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-26 English
ANNOUNCEMENT OF INTERIM RESULTS 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'ANNOUNCEMENT OF INTERIM RESULTS 2021' and contains detailed unaudited consolidated interim financial statements for the six months ended 30 June 2021, including profit and loss, financial position, segment information, notes on accounting policies, and taxation. It references HKAS 34 'Interim Financial Reporting' and includes substantive financial data and analysis for the interim period. The length of the document (15,000 characters) and the presence of detailed financial statements confirm it is a full interim report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-26 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.